Continuous bioprocessing for biologics manufacturing is being adopted in the biopharmaceutical industry by big players such as Merck. Pall Life Sciences has partnered with Merck to help bring this innovative technology platform to fruition.
In this webinar, Pall’s development journey in continuous bioprocessing will be described along with highlights of recent technology advances
Merck will present the development of a continuous Protein A chromatography process step using KANEKA KanCapA™ for the capture of a therapeutic mAb. The method was developed initially in a batch mode and then transferred to the Cadence BioSMB PD system. This five column process was then successfully scaled-up 150-fold using the Cadence BioSMB Process system. The entire process development and scale-up was completed within four weeks and described in detail along with the process economic benefits of using multi-column chromatography.
Participants will learn:
- How to reduce facility footprint, capital expenses, and product cost of goods
- How to improve your process productivity, flexibility, and further facilitate the utilization of single-use and/or disposable technologies
Dr Peter Levison, Senior Marketing Director- Downstream Processing, Pall Life Sciences
Dr Mark Brower, Principal Scientist, Merck
BIA 2017 Supporters